Pharma Mar, S.A.

PharmaMar develops and sells cancer medicines inspired by compounds found in marine organisms. It earns revenue from its own drug sales, manufacturing and licensing agreements, and royalties when partners sell its treatments.

Log in to follow
PHM · BME

Overview

Summary

PharmaMar began in 1986 with a search for potential medicines in marine organisms. The Madrid-based group now combines a commercial oncology business with research into new drugs. Yondelis contains trabectedin; Zepzelca contains lurbinectedin. It sells in selected European markets and relies on partners, including Jazz Pharmaceuticals in the US, elsewhere. Its subsidiary Sylentis also researches medicines that silence particular genes. Each treatment’s approved uses depend on the country.

Latest results

Jan–Sep 2026

Revenue
EUR 146.9 million+12.2%
Operating profit
EUR 6.9 million-59.9%
Cash held
EUR 44.6 million
Financial debt
EUR 67.1 million

Latest financial publication

Oct 29, 2026 · Issuer publication

9M 2026 financial results

Search companies & research

Search companies & research